Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/06
End: 02/28/09
Due: 02/28/10
Phase: N/A
Priority: Normal
Start: 10/31/08
End: 06/30/11
Due: 06/30/12
Phase: N/A
Priority: Normal
Start: 10/31/07
End: 12/31/11
Due: 12/31/12
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma | NCT00374179 | Adnexus, A Bristol-Myers Squibb R&D Company | user2@example.com | None | 2006-08-31 | 2009-02-28 | 2010-02-28 | - | - | 2025-07-14 |
| CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme | NCT00768911 | Adnexus, A Bristol-Myers Squibb R&D Company | user2@example.com | None | 2008-10-31 | 2011-06-30 | 2012-06-30 | - | - | 2025-07-14 |
| CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | NCT00562419 | Adnexus, A Bristol-Myers Squibb R&D Company | user2@example.com | None | 2007-10-31 | 2011-12-31 | 2012-12-31 | - | - | 2025-07-14 |